Transdermal contraceptive patch - a new birth control option
Record ID 32002000297
To summarise the available evidence on the transdermal contraceptive patch.
Authors' recomendations: - A new, once-weekly contraceptive patch (Ortho Evra TM) that delivers transdermally norelgestromin and ethinyl estradiol was approved by the U.S. FDA November, 2001. - Patch drug delivery systems theoretically offer advantages over oral therapy, including enhanced adherence to treatment regimen and reduction in adverse events. - A randomized controlled trial (RCT) demonstrated better adherence to the treatment regimen, with the patch when compared to an oral contraceptive (OC). - However withdrawals due to adverse events and participant choice were higher in patch users than in OC users. - An RCT covering six or 13 menstrual cycles indicated that the short-term efficacy of the patch was similar to that of the OC, but the risk of pregnancy in the long term is not known.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/research/index.html
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Contraceptive Agents, Female
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.